Nexentis Technologies Inc. (MUN:80W0)
Germany · Delayed Price · Currency is EUR | Market Cap | 829.05K -90.4% |
| Revenue (ttm) | n/a |
| Net Income | -14.03M |
| EPS | -30.12 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 0.5042 |
| Previous Close | 0.4601 |
| Day's Range | 0.5042 - 0.5042 |
| 52-Week Range | 0.4601 - 6.1280 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About Nexentis Technologies
Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company’s pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational chemistry platform; and novel in-vitro screening platforms; and advanced ... [Read more]
News
Nexentis: MitoCareX Bio Advances AI-Driven Drug Discovery Initiative with Boltz, Completing Initial Computational Screening Stage
MitoCareX considers preliminary, not yet experimentally validated, computational findings encouraging for further computational analysis and experimental investigation
Nexentis: MitoCareX Bio Deploys its Computational Drug Discovery Infrastructure on Google Cloud
Deployment on Google Cloud Platform is designed to enhance computational capacity, data governance and operational flexibility as MitoCareX advances its drug discovery programs
Nexentis Technologies appoints Major to Scientific Advisory Board
Nexentis Technologies (NXTS) announced that Prof. Dan Major has joined the Scientific Advisory Board of its wholly owned subsidiary, MitoCareX Bio.
Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory Board
Leading computational chemistry expert to advise MitoCareX as it expands its in silico drug-discovery capabilities Ness Ziona, Israel, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (“N...
Nexentis subsidiary evaluates ways for obtaining proteins in in-vitro research
Nexentis Technologies (NXTS) announced that its wholly-owned subsidiary, MitoCareX Bio, is evaluating additional approaches for obtaining proteins used in its in-vitro research activities. MitoCareX i...
Nexentis: MitoCareX Evaluates Expanded Protein Capabilities to Enhance Flexibility and Support Future Drug Discovery
Evaluation of additional commercially available approaches for obtaining proteins is intended to enhance access to research materials, increase research flexibility and support the advancement of Mito...
Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign
Following its broad structural analysis of the human SLC transport protein family, MitoCareX advances from a pool of candidates to a prioritized target, reflecting continued execution of its MITOLINE ...
Nexentis Technologies registers to sell 2.57M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 2.57M shares of common stock. The company is not selling any…
Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter Drug Discovery with Broad Analysis and International AI Initiative
MitoCareX Bio completes comprehensive SLC transport protein analysis to support discovery of small molecules for hard-to-treat cancers and inflammatory metabolic diseases and enters an AI-driven small...
Nexentis Technologies announces monetization of Melz solar investment
Nexentis Technologies (NXTS) announced the signing of an addendum to the loan and partnership agreement, together with Solterra Renewable Energy and the other lenders, for its Melz solar PV project…
Nexentis Announces Monetization of Part of its Melz Solar Investment at $14.5 Million Project Valuation – Significant Premium to Initial Investment
Neve Yarak, Israel, June 29, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis” or the “Company”), a drug discovery company that also invests in solar energy assets based o...
Nexentis Technologies Inc trading halted, volatility trading pause
09:35 EDT Nexentis Technologies (NXTS) Inc trading halted, volatility trading pause
Nexentis Technologies Inc trading resumes
09:40 EDT Nexentis Technologies (NXTS) Inc trading resumes
Nexentis Technologies Announces International AI Drug Discovery Initiative Between MitoCareX Bio and Boltz to Accelerate Novel SLC Small-Molecule Discovery
MITOLINE ® -Enabled 3D Structural Modeling and Boltz AI Capabilities to Be Combined by MitoCareX in a Synergistic Virtual Screening Campaign for selected Transporter Targets
Nexentis: Subsidiary MitoCareX Bio Successfully Completed Broad Analysis of SLC Transport Proteins to Support Discovery of Hard-to-Treat Cancers and Metabolic Diseases
Ness Ziona, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based o...
Nexentis Technologies Inc trading resumes
15:48 EDT Nexentis Technologies (NXTS) Inc trading resumes
Nexentis Technologies Inc trading halted, volatility trading pause
15:38 EDT Nexentis Technologies (NXTS) Inc trading halted, volatility trading pause
Nexentis Technologies says MitoCareX Bio achieves drug discovery milestone
Nexentis Technologies (NXTS) announced that its wholly owned subsidiary, MitoCareX Bio achieved its first drug discovery milestone since its acquisition by Nexentis: the generation of an optimized hit...
Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development
Ness Ziona, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on...
Nexentis Technologies Announces Optimization of Hit Molecule at MitoCareX Bio Representing Key Drug Discovery Milestone
MITOLINE ® -Powered Platform Delivers Optimized Hit Molecule, Strengthening the Foundation for Future Pre-Clinical and Commercial Development
Nexentis Technologies Inc trading halted, volatility trading pause
09:30 EDT Nexentis Technologies (NXTS) Inc trading halted, volatility trading pause
Nexentis Technologies Inc trading resumes
09:35 EDT Nexentis Technologies (NXTS) Inc trading resumes
Nexentis Technologies announces Mitoline U.S. trademark registration approval
Nexentis Technologies (NXTS) announced that its wholly owned subsidiary, MitoCareX Bio, has received official trademark registration from the USPTO for its proprietary algorithm platform, Mitoline. Mi...
Nexentis Technologies Announces U.S. Trademark Registration Approval for MitoCareX's Algorithm Platform MITOLINE™
Neve Yarak, Israel, May 05, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS), (“Nexentis” or the “Company”), a drug discovery company that is also invests in solar energy assets base...
Nexentis Technologies files $100M mixed securities shelf
16:18 EDT Nexentis Technologies (NXTS) files $100M mixed securities shelf